Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer Lymphedema
Phase NA
Enrollment 54
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is conducted to compare between efficacy of large and small area of low-level laser therapy (LLLT) in treatment of post mastectomy lymphedema. The change of severity of BCRL will be measured by the difference of circumference and skin thickness, detected by ultrasound. The influence on clinical symptoms, such as pain, shoulder mobility and hand function, are also investigated in the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Large-area low-level laser therapy(Venusure) — The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
  • Device: Conventional low-level laser therapy — The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.

Primary Outcomes

  • Circumference discrepancy of bilateral upper arm (Day 30 (change of circumference discrepancy of bilateral upper limbs, comparing with the data in baseline) of each section)
  • Circumference discrepancy of bilateral upper arm (Day 60 (change of circumference discrepancy of bilateral upper limbs, comparing with the data in baseline) of each section)
  • Circumference discrepancy of bilateral upper arm (Day 120 (change of circumference discrepancy of bilateral upper limbs, comparing with the data in baseline) of each section)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-24
Completion: 2025-10-31
Eligibility
Age: 20 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 54 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Principal Investigators:
  • Chueh-Hung Wu, PHD (STUDY_CHAIR) - Department of Physical Medicine and Rehabilitation, National Taiwan University Hospital, Taipei, Taiwan
Contact Information
Study Contact:
Ying-Chun Chen, MD
23123456
yasandy2000@gmail.com
Ying-Chun Chen, MD
23123456
yasandy2000@gmail.com
National Taiwan University Hospital
Interventions
  • Device: Large-area low-level laser therapy(Venusure) — The wavelength was 980±15nm, average dose was 10-40nm/cm2 and maximal output was 1000mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions
  • Device: Conventional low-level laser therapy — The wavelength was 808 nm and maximal output was 60 mW. Total treatment duration was 30 min and frequency was 3 sessions/week for 4 weeks; for a total of 12 sessions.
Study Locations (1 sites)
National Taiwan University Hospital, Taipei, Taiwan
Eligibility Criteria
Inclusion Criteria: * Female subjects, 20 years age or older, suffered from unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection) * Stage I or II unilateral secondary upper extremity lymphedema(as defined by the International Society of Lymphology) * Girth≥ 2 cm circumferential difference compared with the uninvolved upper extremity at any 4 cm segment * Able to commit to a long-term follow-up schedule Exclusion Criteria: * Metastatic cancer(stage IV) * Pregnancy * Presence of other extremity lymphedema (primary or secondary) * History of deep vein thrombosis * Pacemaker * Artificial joints, implant or tattoo(area≥4 cm2) at the involved upper extremity * Previous treatment with low-level laser therapy (within 3 months) * Body mass index (BMI) \> 35 (morbid obesity) * High bleeding tendency(hemophilia) * Receiving long-term steroid treatment (oral or systemic)
Conditions Hypertension, Rheumatoid Arthritis
Phase NA
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Rheumatoid arthritis (RA) is a autoimmune disease associated with an increased risk of developing coronary artery disease (CAD) and premature death,. Traditional CAD risk factors like hypertension (HTN) are both very common and poorly controlled among RA patients. Patients with RA face significant challenges in controlling HTN. The goal of this project is to identify barriers to HTN care in patients with RA to reduce CAD events.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Blood pressure intervention arm — The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.

Primary Outcomes

  • Intervention feasibility as measured by participant accrual rates (6 months)
  • Intervention feasibility as measured by participant retention (6 months)
  • Intervention feasibility as measured by adherence to blood pressure monitoring (6 months)
  • Intervention feasibility as measured by adherence to survey reporting (6 months)
  • Intervention feasibility as measured by sample characteristics (6 months)
  • Intervention feasibility as measured by use of resources (6 months)
  • Intervention feasibility as measured by sustainability of data collection procedures (6 months)
  • Intervention acceptability as measured by qualitative interviews (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-16
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Duke University
Collaborators: National Institute on Minority Health and Health Disparities (NIMHD)
Contact Information
Study Contact:
Isaac Smith, MD
919-613-2243
isaac.smith063@duke.edu
Edna Scarlett
919-684-6150
edna.scarlett@duke.edu
Duke Health System
Isaac Smith, MD
919-613-2243
isaac.smith063@duke.edu
Duke Health System
Interventions
  • Behavioral: Blood pressure intervention arm — The intervention will focus on empowering patients to actively participate in their HTN care, facilitating patient-provider communication, and creating a cohesive care team to close the coordination loop for HTN management. This pilot intervention will help achieve these goals by providing participants with home blood pressure monitors and teaching, improving patient-provider communication regarding blood pressure and RA management, and initiating care coordination between rheumatology and primary care providers.
Study Locations (1 sites)
Duke Health System, Durham, North Carolina 27710 United States
Eligibility Criteria
Inclusion Criteria: * 18 years old or older * Uncontrolled hypertension * History of rheumatoid arthritis * Receive both primary care and rheumatology care from Duke Health System Exclusion Criteria: * Age less than 18 years old * Healthy volunteers without rheumatoid arthritis and hypertension * Do not receive both primary care and rheumatology care from Duke Health System * Cognitive impairment with lack the capacity to consent to study participation * Pregnant women * Prisoners
Conditions Breast Cancer
Phase PHASE3
Enrollment 126
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To compare the outcomes of and responses to 2 different radiation therapy schedules (the standard radiation amount and number of doses versus less radiation and fewer doses) that are being given before having breast cancer surgery (cancer removal and reconstruction).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Group 1 (preoperative radiation hypofractionated) — radiation schedules/regimens before your scheduled breast surgery
  • Other: Group 2 (preoperative radiation conventionally fractionated) — radiation schedules/regimens before your scheduled breast surgery

Primary Outcomes

  • Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 (through study completion; an average of 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-04-05
Completion: 2028-11-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 126 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: M.D. Anderson Cancer Center
Collaborators: Artidis
Principal Investigators:
  • Benjamin D. Smith, MD (PRINCIPAL_INVESTIGATOR) - M.D. Anderson Cancer Center
Contact Information
Study Contact:
Benjamin D. Smith, MD
(713) 563-2380
bsmith3@mdanderson.org
Benjamin D. Smith, MD
713-563-2380
bsmith3@mdanderson.org
M D Anderson Cancer Center
Benjamin D. Smith, MD
M D Anderson Cancer Center
Interventions
  • Radiation: Group 1 (preoperative radiation hypofractionated) — radiation schedules/regimens before your scheduled breast surgery
  • Other: Group 2 (preoperative radiation conventionally fractionated) — radiation schedules/regimens before your scheduled breast surgery
Study Locations (1 sites)
M D Anderson Cancer Center, Houston, Texas 77030 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older * Histologic diagnosis of invasive breast cancer (cytologic or histologic confirmation of nodal metastasis is sufficient to establish this eligibility criteria). * Clinical and/or pathologic stage T3-T4c OR N1-N3; for the IBC pilot cohort only, the stage requirement is T4d, any N, M1 * Mastectomy is the planned oncologic surgery but has not yet been performed at the time of protocol enrollment * Autologous (i.e. tissue-based) reconstruction is planned with either a free or rotational flap. * For patients with HER2 positive, non-IBC breast cancer treated with neoadjuvant chemotherapy, one of the following criteria must be met: 1. Residual invasive disease should be documented in either the breast or a regional nodal metastasis after neoadjuvant chemotherapy. This specific eligibility criteria can be satisfied by the post-chemotherapy standard of care breast biopsy. For this matter, the patient may be enrolled on the trial prior to biopsy. If the biopsy does not show residual invasive disease, then the patient will not proceed with protocol-directed therapy and will be removed and replaced from the study. 2. Medical oncologist has documented a discussion in the chart about potential risks of proceeding with PreMRT with regard to impact on adjuvant systemic therapy decisions and the patient has opted to proceed with trial enrollment * For T4d pilot cohort patients, post-chemotherapy, pre-radiation ultrasound must demonstrate at least partial response in the breast and regional lymph nodes and no suspicious infraclavicular, internal mammary, and supraclavicular lymph nodes. * Ability to provide written informed consent in accordance with institutional policies. Exclusion Criteria: * Patients undergoing treatment for recurrent breast cancer in the index breast or lymph nodes. * History of therapeutic irradiation to the breast, lower neck, mediastinum or other area(s) that will overlap with the affected breast. * Presence of active scleroderma * Patients who are pregnant.
Conditions Metastatic Breast Cancer
Phase PHASE2
Enrollment 202
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Aromatase inhibitor (AI) + CDK4/6 inhibitor is settled down as the standard first line therapy for HR+/HER2- metastatic breast cancer and all three CDk4/6 inhibitors, palbociclib, ribociclib, and abemaciclib are currently available for same indications. However, there is no effective treatment strategy for patients who have progressed on AI+CDK4/6 inhibitor. In particular, the clinical efficacies of subsequent hormone therapy are lowered when ESR1 mutations, one of mechanisms of AI resistance occur. In the PADA-1 trial, when ESR1 mutations in ctDNA were detected in patients treated with AI+CDK4/6 inhibitor, AI was switched to fulvestrant even if disease progression was not confirmed clinically. As a result, the median PFS was prolonged by about 8 months in this switching group compared to the group in which AI was continued. The results of this study suggested that delaying the occurrence of ESR1 mutations and early response to them are necessary to increase the effectiveness of hormone therapy. In SWOG S0226 study, fulvestrant + AI combination showed significant benefits in PFS and OS compared to AI monotherapy as the first line therapy. Based on these results, the NCCN guideline suggests fulvestrant + AI combination as one of the first line hormone therapy options. However, the clinical effect of AI + fulvestrant + CDK4/6 inhibitor has not been investigated yet. Therefore, the investigators are planning to compare the clinical efficacy of AI+ fulvestrant + CDK4/6 inhibitor and AI+CDK4/6 inhibitor, and to investigate if a triple combination regimen can delay the emergence of ESR1 mutations and modulate occurred ESR1 mutations.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Fulvestrant plus AI plus ribociclib — Fulvestrant + AI + ribociclib +/- GnRH agonist
  • Drug: AI plus ribociclib — AI + ribociclib +/- GnRH agonist

Primary Outcomes

  • 24 month- progression free survival rate (the time from randomization until documented disease progression or death from any cause, whichever occurs first, assessed up to 24 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-05-31
Completion: 2029-06-30
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 202 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Korea University Guro Hospital
Contact Information
Study Contact:
In Hae Park, MD
+82-2-2626-3172
parkih@korea.ac.kr
Korea university Guro hospital
Jieun Lee, prof
+82-2-
befamiliar@catholic.ac.kr
St Mary Hospital
Interventions
  • Drug: Fulvestrant plus AI plus ribociclib — Fulvestrant + AI + ribociclib +/- GnRH agonist
  • Drug: AI plus ribociclib — AI + ribociclib +/- GnRH agonist
Study Locations (2 sites)
Korea university Guro hospital, Seoul, South Korea
St Mary Hospital, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Female ≥ 19 years of age * Histologically confirmed unresectable, locally advanced or metastatic invasive breast cancer with hormone receptor positive/HER2 negative * No previous history of systemic endocrine or chemotherapy for metastatic, advanced breast cancer. * If the patient has received AI as adjuvant endocrine therapy, the treatment free interval (TFI) should be more than 12 months after the end of adjuvant endocrine therapy. If the patient has received tamoxifen for adjuvant endocrine therapy, TFI less than 12 months will be allowed. * ECOG PS 0-2 * Patients should have measurable or evaluable lesion based on RECIST version 1.1 * Patients should have adequate organ function: * ANC (absolute neutrophil count) ≥ 1.5 × 109/L * Platelet ≥ 100 × 109/L * Serum Hb ≥ 9.0 g/dL * INR ≤1.5 * Serum creatinine ≤ 1.5 X ULN * ALT \& ALT \<2.5 X ULN, if patients have hepatic metastasis, ALT \& ALT \<5.0 X ULN is allowed * Total serum bilirubin \<1.5 X ULN, if patients have hepatic metastasis, Total serum bilirubin \<3.0 X ULN is allowed. * In the case of childbearing potential, patients who can adhere to appropriate contraception during the study period and for at least 6 months after the end of study treatment. * Patients who understand the contents of the clinical trial and are cooperative with the process of the clinical trial. Exclusion Criteria: * Patients with a history of previous treatment with a CDK4/6 inhibitor or other systemic treatment for advanced/metastatic breast cancer * Patients who have received prior treatment with fulvestrant and any investigational ER-directed therapy including SERDs (selective estrogen receptor degrader) * Patients who have disease recurrence on aromatase inhibitor treatment as adjuvant endocrine therapy * Patients who have symptomatic or untreated central nervous system metastasis * Patients who have a history of cardiovascular disease or heart failure as following conditions; within at least 6 months of myocardial infarction, unstable angina, or uncontrolled arrhythmia. * Patients having visceral crisis which needs rapid tumor reduction * Patients who have a history of any other cancer (except nonmelanoma skin cancer, carcinoma in-situ of the cervix, well-differentiated thyroid cancer) * Patients unable to cooperate with periodic blood samples collection * Patients who have active HBV, HCV infection, immune-suppressive disease, or HIV infection. In case of chronic HBV infection, HBV DNA should be negative. Patients with complete remission of HCV infection are allowed. * Pregnant or breast-feeding women * Patients who are considered to be unsuitable for this trial by investigators.
Conditions Postpartum Depression
Phase NA
Enrollment 900
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to test whether an established preventive intervention (group interpersonal therapy) delivered virtually shows the same benefits for preventing postpartum depression as it does when delivered in person.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Behavioral: ROSE Program: In Person — In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
  • Behavioral: ROSE Program: Virtual — Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.

Primary Outcomes

  • Symptom Checklist 20 (SCL 20) (6 weeks after birth)
  • Symptom Checklist 20 (SCL 20) (3 months after birth)
  • Symptom Checklist 20 (SCL 20) (6 months after birth)
  • Symptom Checklist 20 (SCL 20) (12 months after birth)
  • Center for Epidemiologic Studies Depression Scale (CES-D) (6 weeks after birth)
  • Center for Epidemiologic Studies Depression Scale (CES-D) (3 months after birth)
  • Center for Epidemiologic Studies Depression Scale (CES-D) (6 months after birth)
  • Center for Epidemiologic Studies Depression Scale (CES-D) (12 months after birth)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-03-13
Completion: 2027-06
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Denver
Collaborators: National Institute of Mental Health (NIMH), Denver Health Medical Center
Principal Investigators:
  • Galena Rhoades, PhD (PRINCIPAL_INVESTIGATOR) - University of Denver
  • Elysia P Davis, PhD (PRINCIPAL_INVESTIGATOR) - University of Denver
Contact Information
Study Contact:
Galena Rhoades, PhD
303-871-4280
Galena.Rhoades@du.edu
Jennifer Hyer, MD
Jennifer.Hyer@dhha.org
Denver Health Medical Center
Interventions
  • Behavioral: ROSE Program: In Person — In-person preventative intervention for postpartum depression that includes content on building social support and communication skills in relationships, navigating the role transition to motherhood, and learning about signs and symptoms of depression after delivery.
  • Behavioral: ROSE Program: Virtual — Virtual ROSE covers the same content (e.g. improving social support and communication) and is delivered by the same facilitators as the in-person intervention via telehealth.
Study Locations (1 sites)
Denver Health Medical Center, Denver, Colorado 80204 United States
Eligibility Criteria
Inclusion Criteria: * English or Spanish speaking * Less than 30 gestational weeks Exclusion Criteria: * None
Conditions Breast Carcinoma, Head and Neck Cancer, ...
Phase NA
Enrollment 130
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This clinical trial evaluates whether home-based respiratory muscle training is useful for minimizing side effects in patients undergoing treatment for cancer. Over-activation of the nervous system during breast cancer treatment can result in heart- and lung-related side effects which have the potential to reduce a patient's quality of life. Aerobic exercise can help prevent the development of these side effects. However, engaging in regular aerobic exercise may be difficult for breast cancer patients who are actively undergoing treatment. Respiratory muscle training (RMT) involves a series of breathing and other exercises that are performed to improve the function of the respiratory muscles through resistance and endurance training. Home-based RMT may represent a more feasible approach for reducing side effects in patients undergoing treatment for breast cancer.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Best Practice — Receive usual care
  • Other: Medical Device Usage and Evaluation — Wear accelerometer
  • Procedure: Respiratory Muscle Training — Undergo RMT
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Proportion of patients who participate in the study (Up to 12 weeks)
  • Proportion of patients who remain on study (Up to 12 weeks)
  • Proportion of patients who perform >= 3 respiratory muscle training (RMT) sessions/week (Up to 12 weeks)
  • Proportion of patients who perform > 70% of their RMT sessions (Up to 12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-16
Completion: 2029-10-16
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 130 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Roswell Park Cancer Institute
Principal Investigators:
  • Ellis Levine, MD (PRINCIPAL_INVESTIGATOR) - Roswell Park Cancer Institute
Contact Information
Study Contact:
ASK RPCI
1-877-275-7724
askrpci@roswellpark.org
Ellis Levine, MD
716-845-3152
Ellis.Levine@roswellpark.org
Roswell Park Cancer Institute
Ellis Levine, MD
Roswell Park Cancer Institute
Interventions
  • Other: Best Practice — Receive usual care
  • Other: Medical Device Usage and Evaluation — Wear accelerometer
  • Procedure: Respiratory Muscle Training — Undergo RMT
  • Other: Survey Administration — Ancillary studies
Study Locations (1 sites)
Roswell Park Cancer Institute, Buffalo, New York 14263 United States
Eligibility Criteria
Inclusion Criteria: * Able and willing to provide written informed consent * Age \>= 21 years old * Diagnosed with solid tumor (e.g., head and neck, thoracic, or breast cancer) * Scheduled to receive at least one dose of chemotherapy or immunotherapy or radiation * Treated at Roswell Park Comprehensive Cancer Center Exclusion Criteria: * Presence of oral mucosal disease including oral mucositis, or oral candidiasis detected at baseline * Have uncontrolled intercurrent illness including, but not limited to, ongoing or active respiratory infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness/social situations that would limit compliance with study requirements * Any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study intervention
Conditions Depression, ECT, Cognitive Change
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Soterix Medical Incorporated 4x1 adapter — Device permits individualized amplitudes
  • Device: Traditional ECT device — FDA approved ECT device with fixed amplitude.

Primary Outcomes

  • Inventory of Depressive Symptomatology - Clinician Rated (4 weeks)
  • Delis Kaplan Executive Function System Letter Fluency (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-09-14
Completion: 2028-01-01
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of New Mexico
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Chris Abbott, MD (PRINCIPAL_INVESTIGATOR) - University of New Mexico
Contact Information
Study Contact:
Chris Abbott, MD
5052720406
cabbott@salud.unm.edu
Megan Lloyd, MS
‭(505) 272-3507‬
meglloyd@salud.unm.edu
Chris Abbott, MD
505-272-2223
cabbott@salud.unm.edu
University of New Mexico Health Science Center
Interventions
  • Device: Soterix Medical Incorporated 4x1 adapter — Device permits individualized amplitudes
  • Device: Traditional ECT device — FDA approved ECT device with fixed amplitude.
Study Locations (1 sites)
University of New Mexico Health Science Center, Albuquerque, New Mexico 87110 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosis of major depressive disorder or bipolar II * Clinical indications for ECT with right unilateral electrode placement Exclusion Criteria: * Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease) * Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder) * Current drug or alcohol use disorder (except for nicotine) * Contraindications to MRI.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 135
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to investigate and validate multi-parametric magnetic resonance imaging (MRI) modalities for assessment of breast cancer response to neoadjuvant chemotherapy in a multi-site and multi-MRI scanner platform setting. This study is conducted at Oregon Health \& Science University (OHSU), University of Washington (UW), and University of Iowa (UI) using Siemens, Philips, and General Electric MRI scanners, respectively. MRI is a type of scan that uses a very strong magnet and no radiation to take very detailed pictures of parts of the body. MRI is often used as standard of care to take pictures of breast tumor(s) before and after chemotherapy treatment in order to measure the tumor size changes in response to treatment, and in order to plan for surgery. MRI is used because the images it takes are very clear and the borders of the tumor can be measured very accurately. However the tumor size alone is often not a good early indicator of whether or not the tumor responds to treatment. Tumor size change usually happens late during the period of treatment, and tumor size measured with MRI after treatment can overestimate or underestimate the residual cancer. This makes it difficult to do the right surgical planning. In addition to measuring tumor size, the MRI scans in this research study will also measure changes in tumor blood vessels and the number of cancer cells per unit of tumor volume. The purpose of this study is to see whether MRI measurements of these functional tumor properties provide better early prediction and evaluation of breast cancer response to neoadjuvant chemotherapy than tumor size measurement. This is an observational study because the MRI procedures are not expected to have an effect on health outcomes. Eligible participants on this study are receiving standard of care neoadjuvant treatment for their cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Diffusion Weighted Imaging — Undergo DW-MRI
  • Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging — Undergo DCE-MRI

Primary Outcomes

  • Compare functional MRI biomarkers with tumor size measurement for early prediction of breast cancer response to neoadjuvant chemotherapy (Through study completion, up to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2010-03-18
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 135 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Corewell Health East
Collaborators: National Cancer Institute (NCI), University of Washington, University of Iowa, Oregon Health and Science University
Principal Investigators:
  • Wei Huang, Ph.D. (PRINCIPAL_INVESTIGATOR) - Corewell Health William Beaumont University Hoospital
Contact Information
Study Contact:
Wei Huang, Chief, MR Rad Imaging Physics, PhD
248-551-6468
wei.huang@corewellhealth.org
Kristen Grant, RN
248-551-0439
Courtney Wille
319-678-2718
University of Iowa
Interventions
  • Procedure: Diffusion Weighted Imaging — Undergo DW-MRI
  • Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging — Undergo DCE-MRI
Study Locations (4 sites)
University of Iowa, Iowa City, Iowa 52242 United States
Corewell Health William Beaumont University Hospital, Royal Oak, Michigan 48073 United States
OHSU Knight Cancer Institute, Portland, Oregon 97239 United States
University of Washington, Seattle, Washington 98109 United States
Eligibility Criteria
Inclusion Criteria: * Patients with histologically confirmed breast cancer who are scheduled to receive standard of care neoadjuvant chemotherapy prior to surgical management * No contraindication for an MRI exam * Normal kidney functional for receiving a standard dose of gadolinium-based MRI contrast agent through IV injection * Not pregnant * Ability to understand and the willingness to sign a written informed consent document. A signed study-specific informed consent must be obtained prior to any study specific procedures Exclusion Criteria: * Patients who would be normally excluded from undergoing an MRI examination - patients with a pacemaker, aneurysm clip, or any other condition that would warrant avoidance of a strong magnetic field * Patients who are unable to cooperate for an MRI exam lasting about 45 min, and/or have known allergic reaction to gadolinium-based contrast agent * Severe claustrophobia precluding subject from undergoing MRI * Patients with acute or chronic kidney dysfunction (estimated glomerular filtration rate \[eGFR\] \< 60 ml/min/1.73 m\^2 as calculated using the Modification of Diet in Renal Disease \[MDRD\] equation) * Pregnant participants are excluded from this study because it is difficult for them to lie prone on the MRI table and because of possible risk to the fetus * Cognitively impaired
Conditions Breast Carcinoma
Phase EARLY_PHASE1
Enrollment 55
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This early phase I studies how well a new 3D ultrasound (3D-US) imaging technology works in evaluating lymph nodes in patients with breast cancer. Ultrasound uses high-frequency sound waves to generate images of the body.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: Ultrasound Imaging — Undergo 3D-US

Primary Outcomes

  • Lymph node diagnosis by radiologist (benign or malignant) (Aim 2) (Up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2023-02-14
Completion: 2027-06-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Collaborators: National Institute for Biomedical Imaging and Bioengineering (NIBIB)
Principal Investigators:
  • Shigao D Chen, PhD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic in Rochester
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Rica Pol
507-422-5118
Pol.Hanarica@mayo.edu
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic in Rochester
Interventions
  • Device: Ultrasound Imaging — Undergo 3D-US
Study Locations (1 sites)
Mayo Clinic in Rochester, Rochester, Minnesota 55905 United States
Eligibility Criteria
Inclusion Criteria: * Patients with lymph node biopsy or lymph node clip placement as per routine clinical care. * Age of 18 or older. Exclusion Criteria: * Vulnerable subjects such as prisoners and adults lacking capacity to consent.
Conditions Bipolar Disorder, Major Depression, Migr...
Phase Not Applicable
Enrollment 1260
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Background: Mood disorders, such as bipolar disorder, can have serious effects on a person s life. People with bipolar disorder are more likely to have heart disease and abuse substances. In this natural history study, researchers would like to learn more about the connection between exercise and mental health in people with and without mood disorders. Objective: To better understand relationships among physical activity, sleep, and mental health. Eligibility: People aged 8 to 60 years with a history of a mood disorder. Healthy spouses and relatives with no mood disorders are also needed. Design: Participants will be in the study up to 2 years. For up to 20 days in a row, at 4 times during the study, participants will: Complete an electronic diary on their smartphone. Participants will answer questions about their mood, health, sleep, and daily activities. Wear an activity monitor, like a wristwatch, that records how much they move. Wear a light sensor, as a necklace, to record the amount of light in their environment. Some participants will do additional tests. Twice during the study, for 3 days in a row, they will: Wear monitors to record their temperature, heart rate, and sleep. Provide saliva samples. Complete cognitive tasks on their smartphone. Participants will visit the NIH clinic 2 times. They will have a physical exam, with blood and urine tests. They will wear a heart monitor. They will ride a stationary bike for 30 minutes. They may have an imaging scan. Some participants will stay overnight. They will go to sleep wearing a cap to measure their brain activity.

Design

Study type: Observational Observational model: Family Based Time perspective: Prospective

Primary Outcomes

  • Scores on standardized questionnaires (Every 6 months)
  • Subjective mood and energy ratings (4x daily)
  • Clinical rating scales (Every 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-11-03
Completion: 2027-07-31
Eligibility
Age: 8 Years and older
Sex: ALL
Volunteers: true
Enrollment: 1260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Kathleen R Merikangas, Ph.D. (PRINCIPAL_INVESTIGATOR) - National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
Kathleen R Merikangas, Ph.D.
(301) 496-7773
familystudy@nih.gov
For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)
800-411-1222
ccopr@nih.gov
National Institutes of Health Clinical Center
Interventions
N/A
Study Locations (1 sites)
National Institutes of Health Clinical Center, Bethesda, Maryland 20892 United States
Eligibility Criteria
* INCLUSION CRITERIA: To be eligible to participate in this study, an individual must meet all of the following criteria: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Aged 8 and older 3. Probands must have at least one first-degree relative agree to participate 4. Affected probands must have a lifetime history of a mood disorder 5. Unaffected probands must have no lifetime history of a mood disorder 6. In good general health as evidenced by medical history 7. Agreement to adhere to Lifestyle Considerations throughout study duration 8. Ability of subject (or Legally Authorized Representative (LAR)) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: The presence of certain medical conditions may interfere with the interpretation or increase risk of medical complications of the assessments including exercise. Therefore, an individual who meets any of the following criteria will be excluded from participation in this study: 1. Pregnancy 2. People in acute episodes of mania or depression (not excluded, but will delay study entry until sufficiently managed to allow participation in study procedures).
Conditions Diabetes Mellitus, Type 2
Phase PHASE2, PHASE3
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will be carried out in 2 emergency departments (at the exit of the emergency room) and 2 external consultations (endocrinology of the CHU FB Monastir and diabetology consultation, Jemmal hospital). Patients over 18 years of age with: -Diabets

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Drug: Atherolive — The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
  • Drug: Placebo Atherolive — The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.

Primary Outcomes

  • rate of continuous glycemic monitoring and Hemoglobin A1C (90 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2023-01-01
Completion: 2025-12-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Monastir
Principal Investigators:
  • Nouira Semir, Pr (PRINCIPAL_INVESTIGATOR) - University of Monastir
Contact Information
Study Contact:
Nouira semir, Pr
73106046
semir.nouira@rns.tn
Bel Hadj Ali khaoula, MD
73106046
belhadjalikhaoula@yahoo.fr
Semir Nouira
73106000
semir.nouira.urg@gmail.com
Semir Nouira
Interventions
  • Drug: Atherolive — The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months.
  • Drug: Placebo Atherolive — The patient will be assigned using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The placebo will be prescribed at a dose of 400 mg once a day for 3 months.
Study Locations (1 sites)
Semir Nouira, Monastir, Monastir Tunisia 5000 Tunisia
Eligibility Criteria
Inclusion Criteria: * Patients over 18 years of age with: * diabetes. Exclusion Criteria: * Exclusion criteria: None.
Conditions Eisenmenger Syndrome
Phase NA
Enrollment 48
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial hypertension associated with congenital heart disease. The syndrome causes chronic hypoxemia, with an increase in erythrocyte mass, which predisposes to thrombotic complications. Pentoxifylline is a xanthine derivative and it is considered as a hemorrheological agent with described effects of reduction in erythrocyte and platelet aggregation, adhesion and activation of leukocytes, and endothelial damage. The main objective of this study is to verify if the chronic oral administration of pentoxifylline to Eisenmenger patients induces an increase in the circulating levels of thrombomodulin, a naturally occurring proteoglycan with anticoagulant, anti thrombotic and anti-inflammatory properties.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Drug: Pentoxifylline — Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days

Primary Outcomes

  • Plasma concentration of Thrombomodulin (3 months and 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-06-03
Completion: 2026-09-30
Eligibility
Age: 10 Years and older
Sex: ALL
Volunteers: false
Enrollment: 48 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Sao Paulo General Hospital
Collaborators: InCor Heart Institute
Principal Investigators:
  • Antonio Augusto Barbosa Lopes, MD (PRINCIPAL_INVESTIGATOR) - InCor Heart Institute
Contact Information
Study Contact:
Antonio Augusto Barbosa Lopes, MD
+55 11 2661-5409
aablopes@usp.br
Mariana Cappelletti Galante, PharmD
+55112661-5709
Mariana.galante@hc.fm.usp.br
MarianaCappelletti Galante, PharmD
+55 11 2661-5709
Mariana.galante@hc.fm.usp.br
Antonio Augusto Barbosa Lopes
Interventions
  • Drug: Pentoxifylline — Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days
Study Locations (1 sites)
Antonio Augusto Barbosa Lopes, São Paulo, Brazil
Eligibility Criteria
Inclusion Criteria: 1. Eisenmenger syndrome in functional class II, III or IV (World Health Organization for Pulmonary Hypertension). 2. Using or not oral anticoagulation with warfarin. Exclusion Criteria: 1. Hospitalized. 2. History of relevant and/or repetitive bleeding. 3. Relevant comorbidities with specific treatments. 4. Systemic syndromes, except Down syndrome. 5. Candidates for surgical treatment of any nature, except dental. 6. Clinically manifest systemic infectious or inflammatory disease. 7. Thrombocytopenia (\<80x10\*9 platelets/L). 8. Patients in chronic anticoagulation regimen other than warfarin. 9. Diabetics individuals. 10. Pregnancy in progress, interruption of contraception or amenorrhea. 11. History of intolerance of pentoxifylline or other xanthine derivatives. 12. "Creatinine clearance" less than or equal to 30 mL/minute.